Search

Subject MEK -- PI3K -- Combination -- Isogenic -- Biomarker

1. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent. (March 2016)

Authors:
Haagensen, Emma J.; Thomas, Huw D.; Mudd, Clare; Tsonou, Elpida; Wiggins, Ceri M.; Maxwell, Ross J.; Moore, Jonathan D.; Newell, David R.
Journal:
European journal of cancer
Issue:
Volume 56(2016)
Page Start:
69
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent. (March 2016)

Authors:
Haagensen, Emma J.; Thomas, Huw D.; Mudd, Clare; Tsonou, Elpida; Wiggins, Ceri M.; Maxwell, Ross J.; Moore, Jonathan D.; Newell, David R.
Journal:
European journal of cancer
Issue:
Volume 56(2016)
Page Start:
69
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search

  • MEK -- PI3K -- Combination -- Isogenic -- Biomarker 2